IDEAYA Biosciences Reports Strong Q1 Results, Advances Oncology Pipeline with FDA Breakthrough Designation
IDEAYA Biosciences reported strong Q1 financial results, with $1.05 billion in cash reserves, and made significant progress in its oncology drug development pipeline, including FDA approvals and clinical trial enrollments.
2 minutes to read